Tools
Tools
Ho, Terence C. S., Chan, Alex H. Y. and Ganesan, A. 
ORCID: https://orcid.org/0000-0003-4862-7999
(2020)
Thirty years of HDAC inhibitors: 2020 hindsight.
Journal of Medicinal Chemistry, 63 (21).
12460–12484.
ISSN 0022-2623
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Download (924kB) | Preview |
Abstract
It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical development for oncology as well as other therapeutic indications. This perspective reviews the biological and medicinal chemistry advances over the last three decades with an emphasis on the design of selective inhibitors that discriminate between the eleven human HDAC isoforms.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Science > School of Pharmacy |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 07 Jul 2020 23:58 |
| Last Modified: | 22 Oct 2022 06:26 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/75951 |
| DOI: | 10.1021/acs.jmedchem.0c00830 |
Actions (login required)
 |
View Item |